Cancer Treatment
6 stories covering cancer treatment — fund closes, LP allocations, regulatory filings, deal flow, and fundraising signals from PipelineRoad's editorial team.
Transgene and NEC Bio Sign License Agreement for TG4050 Development
Transgene and NEC Bio have signed a license agreement to advance TG4050 for head and neck cancer, involving payments in shares and cash.
Transgene and NEC Bio Sign License for TG4050 Development in Head and Neck Cancers
Transgene and NEC Bio announced a license agreement on April 2, 2026, for advancing TG4050, a personalized vaccine for HPV-negative head and neck cancers, including financial payments to NEC.
Transgene and NEC Bio Sign License for TG4050 Development
Transgene and NEC Bio have signed a license agreement to advance TG4050 for HPV-negative head and neck cancer treatment, including financial payments.
Transgene and NEC Bio Sign License for TG4050 in Head and Neck Cancer
Transgene and NEC Bio have signed a license agreement to advance TG4050's development for resected HPV-negative head and neck cancer, including financial terms like a €2.5 million technology access fe
BriaCell and BriaPro Close Asset Purchase for Soluble CD80 License
BriaCell Therapeutics Corp. and BriaPro Therapeutics Corp. completed an asset purchase transaction for the exclusive Soluble CD80 license, as announced on March 31, 2026.
BriaCell and BriaPro Complete Asset Purchase for Soluble CD80 License
BriaCell Therapeutics Corp. and BriaPro Therapeutics Corp. announced the closing of an asset purchase transaction for an exclusive cancer treatment license, involving share issuance and a credit facil
